荆花胃康胶丸联合PPI三联治疗幽门螺杆菌阳性80例

The effect of JinghuaWeikang capsule and PPI trilogy on the treatment of Helicobacter pylori infection in 80 cases

目的:观察荆花胃康胶丸联合PPI三联治疗幽门螺杆菌(Hp)感染的疗效。方法:将在本院就诊,经14C,13C尿素呼气试验确诊为Hp阳性的患者80例,随机分为两组:①治疗组即荆花胃康组(40例):兰索拉唑+呋喃唑酮+克拉霉素分散片+荆花胃康胶丸,bid,疗程7d。②三联对照组(40例):兰索拉唑+呋喃唑酮+克拉霉素分散片,bid,疗程7d。分别于治疗后7d和30d观察临床症状的缓解程度。疗程结束后4周进行14C或13C尿素呼气试验检测Hp。结果:Hp阳性患者中,荆花胃康组和三联对照组的Hp根除率分别为92.5%和62.5%,差异有显著学显著性,并且在治疗后患者嗳气、上腹胀及上腹痛等临床症状缓解方面,荆花胃康组明显优于三联对照组(P<0.05)。结论:荆花胃康胶丸联合PPI三联在Hp根除率方面与传统三联法相比明显升高,且在治疗后临床症状缓解方面治疗组优于对照组。

Objective： To observe the effect of JinghuaWeikang capsule and PPI trilogy on the treatment of Helicobacter pylori infection. Methods ： 80 patients diagnosised with Helicobacter pylori infection by pathology or 14 C or 13C breath test were randomly divided into the trial group and the control group. The trial group was treated with lansoprazole, Furazolidone, Clarithromyein and JinghuaWeikang Capsule, twice a day; and the control group were treated with lansoprazole. Furazolidone and Clarithromycin twice a day, the time of therapy in both two groups was7 days. The therapy effects were observed at the 7th day, 30th day after treatment and the patients were carried out the 14C or 13C breath test at the 4th week afer treatment. Results： Among the patients with Helicobacter pylori infection, the eradicating rate in the trial group was 92.5% and 62.5% in the control group （P 〈0.05）. The effect of relieving symptoms including abdominal pain, belching and abdominal distension in the trial group was significantly superior to those in the control group. Conclusion： JinghuaWeikang capsule combined with the trilogy is better than single trilogy both in eradicating Helicobacter pylori infection and relieving symptoms including abdominal pain, belching and abdominal distension.